SCOTUS further restricts generics suits

A decision by the U.S. Supreme Court on Monday in Mutual Pharmaceutical Co. v. Bartlett will further restrict the ability of patients to hold generic drug manufacturers liable for injuries. In a 5-4 URL Pharma Inc. and part of Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA).

In 2010, the U.S. District Court for the District of New Hampshire ruled that Mutual's sulindac was unreasonably dangerous because SJS and TEN were only listed in the adverse reaction section of the drug's label and should have been explicitly stated in the drug's warning section. ...